- 2019
-
Press releases - 11.07.2019
High-risk pregnancy: the interferon effect
Des chercheurs ont identifié un nouveau mécanisme cellulaire qui altère la formation du placenta et pourrait ainsi provoquer des complications graves pendant la grossesse. Il est lié à la production d’interféron, une molécule qui est produite en réponse à certaines infections, notamment virales.
-
Press releases - 10.07.2019
Anaphylactic shock: IgG antibodies and neutrophils play an unexpected role
Anaphylactic shock, an exacerbated allergic reaction that can prove fatal, is sometimes caused by the use of drugs during surgery. In most of these extreme reactions, evidence can be provided that patients have anti-drug antibodies of the IgE class. In 10 to 20% of anaphylactic cases evidence for the involvement of anti-drug IgE is lacking. Anti-drug IgE enable activation of mast cells and basophils that release histamine, a potent mediator involved in anaphylaxis. Teams of researchers have successfully identified a new pathological mechanism responsible for these previously unexplained cases.
-
Press releases - 09.07.2019
New Antibiotics Developed by Inserm and Université de Rennes 1
Researchers from Inserm and Université de Rennes recently identified a new bacterial toxin which they transformed into potent antibiotics active against various bacteria responsible for human infections.
-
Press releases - 08.07.2019
In France, 2 out of every 100 women are subjected to violence during their pregnancy
A joint team of researchers from Inserm and the University of Paris has investigated the frequency of physical abuse during pregnancy, its consequences for the mother and child, and the characteristics associated with this violence.
-
Press releases - 28.06.2019
Art and Science program: Inserm at the Rencontres d’Arles and Avignon Festival
Inserm is reaching out to a new audience among the general public this summer by taking part in two events that bring together art and science in a mutually enriching way: the 8th Recherche de l’art (Art of Research) exhibition at the Rencontres d’Arles, in partnership with the École nationale supérieure de la photographie, and the 10th edition of the binôme program at the Avignon Festival, led by the Les sens des mots theater company.
-
Press releases - 27.06.2019
No rest for neurons during sleep
An Inserm team has provided the first description of the behavior and language of the neurons responsible for memory consolidation during sleep.
-
Press releases - 26.06.2019
Acting on the immune system even before cancer develops may be feasible
Researchers have shown that using immunotherapies at very early stages could potentially help prevent cancer.
-
Press releases - 25.06.2019
A New Therapeutic Target for Treating Spinocerebellar Ataxias?
Les ataxies spinocérébelleuses sont des maladies génétiques neurodégénératives du cervelet et du tronc cérébral qui entrainent de nombreux troubles moteurs, et dont la forme la plus connue est la maladie de Machado-Joseph. Une équipe de l’Institut du cerveau et de la moelle épinière, a découvert avec son équipe le rôle crucial d’une enzyme qui permet d’améliorer les symptômes de la maladie chez la souris.
-
Press releases - 24.06.2019
When Moss Reflects Air Pollution
Despite the increasing research into and recognition of the role of particulate matter in the excess mortality caused by air pollution, it is still poorly understood. A research team used an innovative method based on the biomonitoring of metal levels in mosses in rural France. Their findings point to a link between long-term exposure to atmospheric metals and excess mortality, even in areas remote from major sources of emissions.
-
Press releases - 20.06.2019
Inserm Research Director Jérôme Galon Wins European Inventor Award 2019
Inserm researcher Jérôme Galon has been honored by the European Patent Office (EPO) for his Immunoscore®, a test that predicts relapse risk in patients with certain forms of cancer. An achievement that encapsulates the missions and results of Inserm, a research institute serving good health for all.